Cliff Asness's LAB Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 488,099 shares of Standard BioTools Inc. (LAB) worth $634,529, representing 0.00% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in LAB, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 432,725 shares. Largest reduction occurred in Q2 2021, reducing 161,162 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Standard BioTools (LAB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Standard BioTools (LAB) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2013 | +9,570 | New Buy | 9,570 | $38.35 |
| Q1 2014 | +26,300 | Add 274.82% | 35,870 | $44.08 |
| Q2 2014 | +400 | Add 1.12% | 36,270 | $29.39 |
| Q3 2014 | -3,500 | Reduce 9.65% | 32,770 | $24.50 |
| Q4 2014 | -24,000 | Reduce 73.24% | 8,770 | $33.75 |
| Q1 2015 | -8,770 | Sold Out | 0 | $0.00 |
| Q1 2016 | +15,863 | New Buy | 15,863 | $8.07 |
| Q2 2016 | +9,324 | Add 58.78% | 25,187 | $9.01 |
| Q3 2016 | -25,187 | Sold Out | 0 | $0.00 |
| Q4 2016 | +16,367 | New Buy | 16,367 | $7.27 |
| Q1 2017 | -16,367 | Sold Out | 0 | $0.00 |
| Q4 2018 | +25,111 | New Buy | 25,111 | $8.60 |
| Q1 2019 | +190,189 | Add 757.39% | 215,300 | $13.29 |
| Q2 2019 | +115,156 | Add 53.49% | 330,456 | $12.32 |
| Q3 2019 | -66,008 | Reduce 19.97% | 264,448 | $4.63 |
| Q4 2019 | -74,650 | Reduce 28.23% | 189,798 | $3.48 |
| Q1 2020 | +57,845 | Add 30.48% | 247,643 | $2.54 |
| Q2 2020 | +40,267 | Add 16.26% | 287,910 | $4.01 |
| Q3 2020 | -124,874 | Reduce 43.37% | 163,036 | $7.43 |
| Q4 2020 | +156,142 | Add 95.77% | 319,178 | $6.00 |
| Q1 2021 | -121,031 | Reduce 37.92% | 198,147 | $4.52 |
| Q2 2021 | -161,162 | Reduce 81.33% | 36,985 | $6.16 |
| Q3 2021 | +15,967 | Add 43.17% | 52,952 | $6.59 |
| Q4 2021 | -52,952 | Sold Out | 0 | $0.00 |
| Q1 2024 | +63,420 | New Buy | 63,420 | $2.71 |
| Q2 2024 | +179,817 | Add 283.53% | 243,237 | $1.77 |
| Q3 2024 | -156,063 | Reduce 64.16% | 87,174 | $1.93 |
| Q4 2024 | -36,987 | Reduce 42.43% | 50,187 | $1.75 |
| Q1 2025 | +432,725 | Add 862.23% | 482,912 | $1.08 |
| Q2 2025 | +129,151 | Add 26.74% | 612,063 | $1.20 |
| Q3 2025 | -123,964 | Reduce 20.25% | 488,099 | $1.30 |
Cliff Asness's Standard BioTools Investment FAQs
Cliff Asness first purchased Standard BioTools Inc. (LAB) in Q4 2013, acquiring 9,570 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Standard BioTools Inc. (LAB) for 31 quarters since Q4 2013.
Cliff Asness's largest addition to Standard BioTools Inc. (LAB) was in Q1 2025, adding 482,912 shares worth $521,545.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 488,099 shares of Standard BioTools Inc. (LAB), valued at approximately $634,529.
As of the Q3 2025 filing, Standard BioTools Inc. (LAB) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Standard BioTools Inc. (LAB) was 612,063 shares, as reported at the end of Q2 2025.